Inari Medical, Inc. (NASDAQ:NARI – Get Free Report) CFO Mitch C. Hill sold 6,000 shares of Inari Medical stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $40.96, for a total transaction of $245,760.00. Following the sale, the chief financial officer now owns 181,294 shares of the company’s stock, valued at approximately $7,425,802.24. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Inari Medical Price Performance
NASDAQ:NARI opened at $38.64 on Friday. The company has a market cap of $2.24 billion, a P/E ratio of -1,288.00 and a beta of 0.84. Inari Medical, Inc. has a one year low of $37.92 and a one year high of $71.85. The firm’s fifty day moving average price is $47.29 and its two-hundred day moving average price is $55.52.
Inari Medical (NASDAQ:NARI – Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.09). Inari Medical had a positive return on equity of 1.23% and a negative net margin of 0.33%. The business had revenue of $132.10 million for the quarter, compared to analyst estimates of $131.82 million. During the same period last year, the firm posted ($0.11) EPS. Inari Medical’s quarterly revenue was up 22.5% on a year-over-year basis. As a group, equities research analysts expect that Inari Medical, Inc. will post -0.39 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
NARI has been the topic of a number of recent research reports. Piper Sandler lowered Inari Medical from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $85.00 to $55.00 in a research report on Thursday, February 29th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $75.00 price target on shares of Inari Medical in a research note on Friday, April 12th. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price objective on shares of Inari Medical in a research report on Wednesday, March 6th. Finally, Truist Financial reduced their target price on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a report on Friday, March 22nd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Inari Medical currently has an average rating of “Moderate Buy” and an average price target of $73.71.
Check Out Our Latest Report on NARI
Inari Medical Company Profile
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Featured Articles
- Five stocks we like better than Inari Medical
- How to Invest in Biotech Stocks
- Comprehensive PepsiCo Stock Analysis
- There Are Different Types of Stock To Invest In
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.